Federal contract award
HHSO100201600007C
IGF::OT::IGF POINT-OF-CARE DIAGNOSTIC ASSAY SYSTEM FOR ANTHRAX
Award details
Obligations, current value and potential value describe different measures; they are never added together.
| Field | Reported value |
|---|---|
| Agency | Department of Health and Human Services |
| Office | BARDA - ASPR / DAAPPO / BARDA DCMA |
| NAICS | 541711 |
| PSC | AN41 — HEALTH R&D SERVICES; HEALTH CARE - OTHER; BASIC RESEARCH |
| Parent award / vehicle | Not reported |
| Set-aside | NO SET ASIDE USED. |
| Pricing type | COST PLUS FIXED FEE |
| Obligations | $19.8M |
| Current contract value | $19.8M |
| Potential contract value / ceiling | $19.8M |
| Start date | May 16, 2016 |
| Current end date | Aug 31, 2023 |
| Potential end date | Aug 31, 2023 |
| Latest award activity | Sep 30, 2025 |
| Source loaded | Sep 26, 2026 |
Funding and modification history
Showing the latest 25 of 25 loaded transactions. Negative values are deobligations.
| Date | Modification | Obligation change | Description |
|---|---|---|---|
| Sep 30, 2025 | P00024 | $-31.4K | THE PURPOSE OF THIS MODIFICATION IS TO DEOBLIGATE FUNDING IN THE AMOUNT OF $31,435.04 IN CANCELLING FUNDS FROM LINE 3. |
| Aug 8, 2024 | P00023 | $-955 | THE PURPOSE OF THIS MODIFICATION IS TO DEOBLIGATE FUNDING IN THE AMOUNT OF $955.33 IN CANCELLING FUNDS FROM LINE 2. |
| Jul 28, 2023 | P00022 | $0 | THE PURPOSE OF THIS BILATERAL MODIFICATION IS TO DESCOPE THE STATEMENT OF WORK (SOW) FOR CLINS 0003 AND 0004. THIS DESCOPE OF WORK WILL ALLOW THE WORK TO RAMP DOWN AND END. |
| Mar 8, 2023 | P00021 | $0 | THE PURPOSE OF THIS BILATERAL MODIFICATION IS TO EXTEND THE PERIOD OF PERFORMANCE OF CLIN 0003, OPTION B1 BY FOUR MONTHS. ACCORDINGLY: 1. CLIN 0003'S PERIOD OF PERFORMANCE ENDING DATE IS EXTENDED FROM 03/31/23 TO 06/30/23. |
| Nov 3, 2022 | P00020 | $0 | THE PURPOSE OF THIS BILATERAL MODIFICATION IS TO: A.) REVISE THE STATEMENT OF WORK FOR CLIN 4 TO REMOVE THE SUPPLEMENTAL CLINICAL STUDIES WITH 220 SUBJECTS, AND REALLOCATE THE COSTS ASSOCIATED WITH THAT EFFORT TO THE REMAINING CLIN 4 WORK. B.)TO |
| Jul 27, 2022 | P00019 | $1.8M | POINT-OF-CARE DIAGNOSTIC ASSAY SYSTEM FOR ANTHRAX |
| Mar 10, 2022 | P00018 | $0 | POINT-OF-CARE DIAGNOSTIC ASSAY SYSTEM FOR ANTHRAX |
| Nov 3, 2021 | P00017 | $0 | EO14042 POINT-OF-CARE DIAGNOSTIC ASSAY SYSTEM FOR ANTHRAX |
| Sep 23, 2021 | P00016 | $5.4M | POINT-OF-CARE DIAGNOSTIC ASSAY SYSTEM FOR ANTHRAX |
| Aug 3, 2021 | P00015 | $528.1K | POINT-OF-CARE DIAGNOSTIC ASSAY SYSTEM FOR ANTHRAX |
| Apr 5, 2021 | P00014 | $0 | TO DEVELOP AN ANTHRAX LETHAL FACTOR (LF) POC DIAGNOSTIC. THE FUNDING WILL SUPPORT THE VALIDATION AND PREMARKET 510(K) SUBMISSION OF THIS RAPID TEST, WHICH WILL BE USED ON THE SAME INSTRUMENT PLATFORM AS THE SRI-DEVELOPED POC BIODOSIMETRY TRIAGE TEST |
| Jan 26, 2021 | P00013 | $0 | TO DEVELOP AN ANTHRAX LETHAL FACTOR (LF) POC DIAGNOSTIC. THE FUNDING WILL SUPPORT THE VALIDATION AND PREMARKET 510(K) SUBMISSION OF THIS RAPID TEST, WHICH WILL BE USED ON THE SAME INSTRUMENT PLATFORM AS THE SRI-DEVELOPED POC BIODOSIMETRY TRIAGE TEST |
| Sep 18, 2020 | P00012 | $0 | TO DEVELOP AN ANTHRAX LETHAL FACTOR (LF) POC DIAGNOSTIC. THE FUNDING WILL SUPPORT THE VALIDATION AND PREMARKET 510(K) SUBMISSION OF THIS RAPID TEST, WHICH WILL BE USED ON THE SAME INSTRUMENT PLATFORM AS THE SRI-DEVELOPED POC BIODOSIMETRY TRIAGE TEST |
| Aug 6, 2020 | P00011 | $0 | TO DEVELOP AN ANTHRAX LETHAL FACTOR (LF) POC DIAGNOSTIC. THE FUNDING WILL SUPPORT THE VALIDATION AND PREMARKET 510(K) SUBMISSION OF THIS RAPID TEST, WHICH WILL BE USED ON THE SAME INSTRUMENT PLATFORM AS THE SRI-DEVELOPED POC BIODOSIMETRY TRIAGE TEST |
| Jun 23, 2020 | P00010 | $5.3M | TO DEVELOP AN ANTHRAX LETHAL FACTOR (LF) POC DIAGNOSTIC. THE FUNDING WILL SUPPORT THE VALIDATION AND PREMARKET 510(K) SUBMISSION OF THIS RAPID TEST, WHICH WILL BE USED ON THE SAME INSTRUMENT PLATFORM AS THE SRI-DEVELOPED POC BIODOSIMETRY TRIAGE TEST |
| Feb 12, 2020 | P00009 | $0 | TO DEVELOP AN ANTHRAX LETHAL FACTOR (LF) POC DIAGNOSTIC. THE FUNDING WILL SUPPORT THE VALIDATION AND PREMARKET 510(K) SUBMISSION OF THIS RAPID TEST, WHICH WILL BE USED ON THE SAME INSTRUMENT PLATFORM AS THE SRI-DEVELOPED POC BIODOSIMETRY TRIAGE TEST |
| Aug 21, 2019 | P00008 | $3.8M | TO DEVELOP AN ANTHRAX LETHAL FACTOR (LF) POC DIAGNOSTIC. THE FUNDING WILL SUPPORT THE VALIDATION AND PREMARKET 510(K) SUBMISSION OF THIS RAPID TEST, WHICH WILL BE USED ON THE SAME INSTRUMENT PLATFORM AS THE SRI-DEVELOPED POC BIODOSIMETRY TRIAGE TEST |
| Apr 29, 2019 | P00007 | $0 | IGF::OT::IGF POINT-OF-CARE DIAGNOSTIC ASSAY SYSTEM FOR ANTHRAX |
| Dec 10, 2018 | 6 | $0 | IGF::OT::IGF POINT-OF-CARE DIAGNOSTIC ASSAY SYSTEM FOR ANTHRAX |
| Oct 5, 2018 | 5 | $0 | IGF::OT::IGF POINT-OF-CARE DIAGNOSTIC ASSAY SYSTEM FOR ANTHRAX |
| Jun 27, 2018 | 4 | $483.8K | IGF::OT::IGF POINT-OF-CARE DIAGNOSTIC ASSAY SYSTEM FOR ANTHRAX |
| Apr 25, 2018 | 3 | $0 | IGF::OT::IGF POINT-OF-CARE DIAGNOSTIC ASSAY SYSTEM FOR ANTHRAX |
| Jan 4, 2018 | 2 | $0 | IGF::OT::IGF POINT-OF-CARE DIAGNOSTIC ASSAY SYSTEM FOR ANTHRAX |
| Sep 27, 2017 | 1 | $0 | IGF::OT::IGF POINT-OF-CARE DIAGNOSTIC ASSAY SYSTEM FOR ANTHRAX |
| May 6, 2016 | 0 | $2.5M | IGF::OT::IGF POINT-OF-CARE DIAGNOSTIC ASSAY SYSTEM FOR ANTHRAX |
Research next steps
- Check the stated set-aside against the solicitation and current certifications.
- Review the award scope and buyer evidence before making a bid/no-bid decision.